In gliomas, the activation of the mTOR pathway, mostly demonstrated in the immunohistochemical overexpression of various effectors, is highly present, but, for now, no extensive data link the Pi3K/AKT/mTor deregulation signature to a specific MAPK-pathway driver in high-grade and low-grade gliomas [56]. This evidence concerns the gene AKT1 and central nervous system cancer.